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Hardly any field in medicine has come under
more scrutiny then the periodic health exam or
medical check-up. The entire population consists
of potential candidates for preventive health serv-
ices. Thus the economic burden resulting from
these interventions is high. These costs must be
outweighed by the benefits resulting from the in-
terventions. Since the candidates for these inter-
ventions are healthy adults the risks involved with
these interventions should be as small as possible
or outweighed by the benefits gained. Conse-
quently it is no surprise that many medical soci-
eties and two North-American national task forces
have reviewed this field and given recommenda-
tions regarding specific interventions. 
This article reviews the history of the periodic
health exam and how a better understanding of
epidemiology, operating characteristics of tests
and medical economics has changed the concept of
the check-up over time to its present status. Cur-
rent recommendations and the evidence they are
based upon are summarised. We will focus on
those interventions with good evidence supporting
either their implementation or rejection. Some
controversial interventions will also be discussed,
but it is beyond the scope of this review to include
all interventions. This review follows the recom-
mendations given by the two North-American task
forces, but differences between them and Euro-
pean strategies are highlighted where applicable.
A guide for interpreting recommendations re-
garding preventive interventions and integrating
guidelines into clinical practice is given.
A growing body of evidence supports preven-
tive interventions in asymptomatic adults. Primary
prevention, which includes counselling (in partic-
ular for smoking cessation) and review of immuni-
sation status, has been shown to be more cost-ef-
fective than secondary prevention. Evidence sup-
ports screening for hypertension, hyperlipidaemia,
cervical cancer, colorectal cancer, breast cancer
and obesity. Screening for lung, pancreatic and
ovarian cancer has no effect on outcome and
should not be performed. Controversial preven-
tive interventions include general screening for
diabetes mellitus, thyroid disorders and prostate
cancer. Physicians should be aware of a possible
hidden agenda in patients presenting for a check-
up.
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Summary
Introduction
History
The idea of performing periodic health exams
in adults was first discussed in the medical litera-
ture of the 19th century [1]. However, it did not be-
come popular until the beginning of the 20th cen-
tury when an uncontrolled study by the Metro-
politan Life Insurance showed that persons un-
dergoing an annual physical examination had a
lower mortality than expected [2]. Based on this
study the American Medical Association recom-
mended the annual physical examination for all
No financial
support to declare.
persons over age 35 [3]. However, this recommen-
dation was never properly implemented and re-
sulted in a small group of wealthy individuals re-
ceiving extensive annual check-ups while a large
majority of the people received little or no pre-
ventive care at all. Thus, the concept of that time,
that a check-up should include a large battery of
laboratory tests and a complete physical examina-
tion (figure 1), gave way slowly to a more selective
and evidence-based approach. The first systematic
review on screening measures for 36 diseases was
published 1975 by Frame and Carlson [4]. In 1979
the Canadian Task Force (CTF) published its first
report [5,6]. In this study rules of evidence to eval-
uate the quality of reported data were introduced.
Subsequently the United States Preventive Ser-
vices Task Force (USPSTF), the American College
of Physicians, and other major groups published
extensive reviews of the scientific evidence sup-
porting specific preventive interventions [8–10].
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Interpreting and integrating guidelines in clinical practice [11]
Some screening or preventive interventions
are clearly effective, with benefit outweighing
harm, such as phenylketonuria screening or
screening for systolic hypertension among the eld-
erly. However, for many interventions the benefit
is less clear or the intervention has considerable
potential to harm. In these situations clinicians
need to know the real benefit, if any, to weigh this
benefit against the potential harm. Finally, indi-
vidual values of the person requesting a test or
qualifying for a preventive intervention should be
integrated into the decision whether to perform
the preventive service. Criteria for evaluating
guidelines or recommendations regarding screen-
ing are presented in table 1 and reviewed below.
Is there good evidence that earlier intervention works?
Guidelines recommending a screening inter-
vention based on a randomised controlled trial
(RCT) comparing the intervention with standard
care relies on strong evidence. Observational stud-
ies might be sufficient to recommend a screening
intervention, if the benefit is evident and potential
harm is minimal. This is the case with cervical can-
cer screening or screening for phenylketonuria.
However if benefit and harm are more evenly bal-
anced, RCTs might be required since observa-
tional studies might be misleading due to lead-time
and/or length-bias. Lead-time bias falsely appears
to prolong survival by adding the asymptomatic to
the symptomatic survival time. Length bias refers
to diseases with a heterogeneous course where
screening seems to improve survival by adding the
oligosymptomatic or slow progressing group to
the disease population. Systematic reviews and
meta-analyses are helpful, if more than one RCT
exists for a specific preventive intervention. An-
other reason to perform a meta-analysis is the pres-
ence of conflicting results.
Were the data identified, selected and combined 
in an unbiased fashion?
Studies upon which guidelines are based
should be derived from a comprehensive search
with specific inclusion and exclusion criteria. The
methodological quality of the studies considered
should be assessed.
What are the benefits?
Benefits of a preventive intervention are
usually a reduction in mortality or an increase in
quality of life. This can be expressed as absolute or
relative risk reduction. The absolute risk reduction
Figure 1
Advertisement for
check-up from last
century. Courtesy
National Library 
of Medicine.
Table 1
User’s Guides for
Guidelines and Rec-
ommendations about
Screening. (From
Barratt et al. [11],
with permission.)
Are the recommendations valid?
Is there randomized controlled trial evidence that earlier 
intervention works? Were the data identified, selected 
and combined in an unbiased fashion?
What are the recommendations and will they help you 
in caring for your patients?
What are the benefits?
What are the harms?
How do these compare in different people and with different 
screening strategies?
What is the impact of people’s values and preferences?
What is the cost-effectiveness?
depends on the baseline risk and thus represents a
more realistic estimate of the size of effect (table
2). The number of people who need to be screened
to prevent an adverse outcome is an alternative way
to measure benefit.
What are the harmful aspects?
Obvious harm arises from complications of
investigations and adverse effects of treatment in
patients with positive test results. Other harmful
aspects to be considered are the anxiety generated
by screening tests and possibly during treatment,
adverse effects of labelling or early diagnosis, un-
necessary treatment of persons with a positive test
result who have an oligosymptomatic or slowly
progressing form of the disease and false reassur-
ance in persons with a false-negative test result.
How does benefit and harm compare in different
people and with different screening strategies?
Benefits and harmful aspects are not evenly
distributed over the population. Persons with a
higher risk for a condition will benefit more from
a preventive or screening intervention. Often the
mortality from a condition increases with age.
Thus, younger persons benefit less from a screen-
ing intervention than older persons. But the ben-
efit of an intervention is also dependent on the life
expectancy. In a very old person the number of life
years gained by a preventive intervention decreases
compared to a younger person due to the limited
life expectancy. Genetic susceptibility for a condi-
tion can also increase the benefit derived from
screening. Furthermore the benefit of screening
increases with a shorter screening interval. But the
same can be said for the harm and costs, which
must be weighed against the increased benefit to
establish an optimal screening interval. Benefits
and harm depend on the type of screening pro-
gram. In general, in population based screening
the risk profile and benefits are lower and the harm
associated with screening higher, compared with
opportunistic screening.
What is the impact of people’s values and preferences?
The decision to participate in screening pro-
gramme depends largely on the individual opinion
about the benefits of the intervention. This view is
based upon the quality of information on the ben-
efit and harm of a preventive intervention that a
person received and the personal beliefs and val-
ues of the individual. 
What is the impact of uncertainty associated 
with the evidence?
Uncertainty for both benefit and harm is ex-
pressed by the 95% confidence interval around a
specific value. Wider intervals increase the uncer-
tainty and an individual test result in such a setting
could be considerably smaller or greater.
What is the cost-effectiveness?
The cost-effectiveness analysis relates the ben-
efit and harm of a preventive service to monetary
units. The result of such an analysis may help in
the decision whether to implement a preventive
intervention. However, one should keep in mind
that the assumptions on which a cost-effectiveness
study is based are subject to change. This possible
change must be addressed in a sensitivity analysis
[12].
Example 
The process of assessing a guideline is demon-
strated for colorectal cancer screening with faecal
occult blood test (FOBT). As outlined below, there
is evidence from several RCTs, that intervention in
the asymptomatic phase reduces colorectal cancer
mortality. The relative risk reduction of 33% from
the 3 largest of these trials translates into an ab-
solute risk reduction of 13 deaths per 1000 persons
screened for 15 years starting at age 50 [11]. For
each person whose cancer death is prevented 9.3
years are gained. This benefit is not similar for all
age groups. High-risk patients between age 60 and
80 benefit the most. The potential harm resulting
from screening these 1000 persons with FOBT are
2263 false-positive tests leading to anxiety, further
work-up by colonoscopy and 19 complications of
colonoscopy such as perforation and bleeding. 
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Table 2
Comparison of data presented as relative and absolute risk reductions and number needed to screen with varying baseline risks of disease and
constant relative risk (from Baratt et al. [11], with permission).
Baseline risk risk in relative absolute no. needed
(risk in unscreened screened risk risk to screen
group), % group, % reduction, % reduction, %
4 2 50 2 50
2 1 50 1 100
1 0.5 50 0.5 200
0.1 0.05 50 0.005 2000
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1. Counselling for all age-groups: prevention of tobacco use, proplem-drinking, domestic violence, sedentary lifestyle, healthy diet and dental hygiene. 
Age-specific: in younger risk-taking adults: prevention of motor vehicle accidents (no speeding, safety belts) and safer sex precautions; in elderly adults: 
minimizing risk for falls, aids for presbyacusis and presbyopia. 
Caveat: in up to 50% of patients presenting for a periodic health exam there is a “hidden agenda”, such as a psychosocial problem.
2. Obesity: Body Mass Index (BMI) >27 kg/m2
3. Screening for cervical cancer with Papanicolaou smears above age 65 is controversial
4. Annual, but not biennial, screening reduces colorectal cancer (CRC) related mortality
5. Recommended by USPSTF and CTF. Recent data (Lancet 2000;355:129) question significant effect on morbidity or mortality
6. Persons who were vaccinated before age 60 should receive a booster at age 65
7. Possible alternative to CRC-screening with yearly Faecal Occult Blood Test
8. High-risk sedentary lifestyle, BMI >27, hypertension, hyperlipidaemia, positive family history, polycystic ovaries
9. Good evidence supports screening women >45 for overt and subclinical hypothyroidism
Table 3
Selected, age-specific preventive interventions with strength of supporting evidence. Adapted from [82].
The two national Task Forces have published
recommendations on performing or not perform-
ing a preventive service based upon scientific evi-
dence [6–9]. Both groups use a similar five-point
scale to grade the strength of the recommendation.
For interventions with a proven benefit “A” or “B”
recommendations were given. “A” recommenda-
tions were given if good evidence, such as large
randomised controlled trials, supports the imple-
mentation. “B” recommendations were given if
fair evidence supports the implementation. Inter-
ventions, which have been shown to be ineffective
or even harmful, were given “D” or “E” recom-
mendations. “E” recommendations were given for
good evidence supporting the exclusion, and “D”
recommendations for fair evidence supporting
their exclusion. “C” recommendations were given
if insufficient evidence exists that the preventive
intervention is or is not effective. This may mean
that appropriate studies have not been conducted
so far or that the available studies have produced
conflicting results. Another reason for a C recom-
mendation is a close call between benefits and
harm. However since more and more randomised
controlled trials are published it is possible that this
system will become insensitive to subtle differ-
ences in the quality of supporting studies [13].
Table 3 summarises selected, preventive interven-
tions and recommendations regarding their im-
plementation on an age-time scale. This grading
system is still in use today. 
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Age
Counselling (1)
BMI (2)
Blood Pressure
Cholesterol
Pap-Smear (3)
Fecal Occult Blood (4)
Mammography (5)
Influenza Vaccination
Pneumococcal Vaccination (6)
Colonoscopy (7)
Fasting Plasma Glucose (8)
Thyroid stimulating hormone TSH (9)
Prostate specific antigen PSA
Good evidence against screening for – lung cancer (Sputum and/or chest x-ray) in general population and smokers
– ovarian cancer (CA 125 and imaging studies)
– pancreatic cancer (CA 19-9 and imaging studies)
– coronary heart disease (EKG or exercise EKG) in general population
A black square  indicates good evidence supporting this counseling or screening measure. 
A grey circle  indicates insufficient evidence to recommend for or against using this intervention.
“Grading” the evidence
Primary prevention
Primary prevention in medicine is more cost-
effective than secondary or tertiary prevention. In
a review on published economic analyses, Tengs et
al. found primary preventive strategies to be four
times more cost effective than secondary or terti-
ary preventive strategies [14]. The two most im-
portant primary preventive measures in medicine
are counselling and immunisations [15]. 
Counselling
Counselling by the physician consists of two
elements. First, problem behaviour must be iden-
tified. This is followed by an appropriate inter-
vention by the physician. Problem behaviours
which should be addressed during the check-up
visit are: tobacco use, sedentary lifestyle, unsafe
sexual practices, unhealthy diet, alcohol excess,
lack of dental hygiene, illicit drugs and injury
prone behaviour [6–9]. The evidence grades sup-
porting counselling on these topics are as follows:
tobacco cessation (USA and CAN: A), wearing seat
belts in cars and helmets on motorcycles or bikes
(USA: A; CAN: B), promotion of physical activity
(USA: A for risk-groups such as diabetics, obese
patients or patients with hypertension, C for all
others; CAN: B), safe sex practices (USA and
CAN: B), healthy diet (USA and CAN: B), screen-
ing with the CAGE questionnaire and counselling
for problem drinking (USA and CAN: B), dental
hygiene (USA: B; CAN: C) [6–9]. Counselling 
to prevent morbidity and mortality from youth
violence or drug use was only evaluated by the
USPSTF and given a “C”-recommendation [8, 9].
Helpful tools to assess the readiness for change of
an unhealthy behaviour and assist a patient in
changing this behaviour exist. One example is the
transtheoretical model of behaviour change devel-
oped by Prochaska and DiClemente [16]. This
model uses a temporal dimension, the stages of
change, to integrate processes and principles of
change from different theories of intervention,
hence the name transtheoretical. The transtheo-
retical model assumes that health behaviour
change involves progression through six defined
stages of change: pre-contemplation, contempla-
tion, preparation, action, maintenance and termi-
nation (figure 2). The distribution among theses
stages in the risk-population of smokers in the
United States is as follows: 40% are in pre-con-
templation, 40% are in contemplation and 20% in
preparation [17–19]. In Switzerland the distribu-
tion in this risk-population is shifted towards the
pre-contemplation stage: 75% are in pre-contem-
plation, 20% in contemplation and 5% in prepa-
ration [20]. The model is based on assumptions,
that: 1) behaviour change is a process that unfolds
over time through this sequence of stages; 2) with-
out planned interventions populations will remain
stuck in the early stages; and 3) specific processes
and principles of change need to be applied at spe-
cific stages if progress through the stages is to
occur. In the pre-contemplation stage the patient
is unaware of his unhealthy behaviour. In this stage
the physicians’ task is to raise consciousness for a
given problem. This is best achieved by linking un-
healthy behaviour to subjective symptoms or signs,
e.g., smoking to dyspnoea or obesity to hyperten-
sion. In the contemplation stage, ambivalence in
the patient is nurtured and thus the progression
into the next stage facilitated. Ambivalence is ex-
perienced as uncomfortable and something has to
be done about it. One strategy to develop ambiva-
lence is to have a patient list the “good things” and
the “less good things” about a problem behaviour.
The positive aspects are then reviewed and sum-
marised with the patient. Then the negative as-
pects are explored more thoroughly and examples
are requested. For example, “You said that your
children are affected by your use of cigarettes. Tell
me about a time that happened”. In the prepara-
tion stage the change should be planned and sup-
port be offered, e.g., set a quit date or offer nico-
tine replacement. In the action and maintenance
stage the role of the physician is to reinforce the
new behaviour and develop a contingency man-
agement, such as alternative strategies to cigarette
smoking after eating. These strategies are stage-
specific. Applying strategies like contingency man-
agement or reinforcement to people in pre-con-
templation or contemplation would represent ef-
forts likely to be unsuccessful and not understood.
Applying the transtheoretical model for smoking
cessation increased the rate of abstinence after 6
months follow-up from 4.7 to 11.2% compared
with an intervention based on self-help manuals
[21]. A recent Swiss study documented the effec-
tiveness of a computerised smoking cessation pro-
gram based on the transtheoretical model of be-
haviour change. Abstinence after 7 months was
5.8% in the intervention group compared with
2.2% in the control group [22].
Counselling should not only be stage-specific,
but also age-specific. When counselling younger
risk-taking adults, the risk of speeding and impact
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Figure 2
The readiness of
change cycle adopted
from Prochaska and
DiClemente [16].
of using safety belts should be brought up. In older
adults minimising the risk for falls in their home
and possible reduced hearing, vision or cognitive
function should be discussed [6–9].
Immunisation in adults
Immunisations in the adult population are
often neglected despite the fact that in the West-
ern hemisphere vaccine-preventable diseases occur
predominantly in adults. In Switzerland approx-
imately 1100 patients die each year from in-
vasive pneumococcal infection and 400 patients
die as a consequence of the annual influenza epi-
demic [23, 24]. These numbers could be reduced
significantly by implementing the recommended
vaccination strategies [25]. Mortality from other
vaccine-preventable diseases is much lower and
less important from an epidemiological point of
view.
Influenza vaccine (USA and CAN: B). The in-
fluenza vaccine is derived from egg-grown viruses
that are highly purified and inactivated. It contains
strains representing the most recent influenza
viruses circulating in the world and believed to be
likely to cause the next epidemic [26]. The efficacy
of the vaccine varies from strain to strain and de-
pends also on the matching of the vaccine with the
strain causing the epidemic. Vaccine efficacy is the
measured protection from clinical and serologi-
cally confirmed disease. In general the efficacy of
the influenza vaccine in young immunocompetent
adults is between 70 and 80%. In adults older than
sixty years the efficacy is between 40 and 60% [27].
Nevertheless, influenza vaccination in this risk
population of adults older than 65 years reduces
pneumonia and hospitalisations by 50% and mor-
tality by 70% [28]. Other risk populations for
which annual influenza vaccination is recom-
mended include nursing home residents, patients
with chronic cardiac or pulmonary diseases, dia-
betics, immunosuppressed patients including HIV-
infected persons, and patients with renal insuf-
ficiency. Peak of serum antibody titres after vac-
cination are to be expected four to six weeks after
immunisation and decrease by 50% after 6
months. From this serologic dynamics stems the
recommendation to immunise the risk-population
between October and November each year [26].
Pneumococcal vaccine (USA: B; CAN: A for in-
stitutionalised persons >55 years of age, C for in-
dependently living persons >55). The 23-valent
polysaccharide vaccine is available all over Europe.
Currently the 7-valent protein-conjugated vaccine
is available in Switzerland, Germany, Italy, France,
Belgium, Denmark, Spain and Portugal. At this
time the 7-valent vaccine is registered only for the
paediatric population. The 23 strains in the poly-
saccharide vaccine cover more than 90% of the
strains responsible for invasive pneumococcal in-
fections in Switzerland [23]. The results of studies
evaluating the efficacy of the vaccine against clin-
ical and radiological pneumonia and invasive in-
fection documented by positive tissue or blood cul-
tures vary. The vaccine does not seem to reduce
the incidence of pneumonia especially in the risk-
population [29]. Its primary benefit is in prevent-
ing invasive disease and death. A study which used
the pneumococcal surveillance system established
by the Centers for Disease Control and Preven-
tion demonstrated a 57% overall efficacy in pre-
venting invasive disease [30]. For Patients with di-
abetes the efficacy was shown to be 85%. For im-
munocompetent persons 65 years or older and pa-
tients with chronic cardiac conditions, the efficacy
rate was 75%. The efficacy in patients with pul-
monary disease was somewhat lower with 65%.
However, in patients with immunosuppression,
myeloproliferative disorders, renal insufficiency or
hepatic failure no efficacy in preventing invasive
pneumococcal infection could be shown [30].
Pneumococcal vaccination should be offered to
persons 65 years and older. If these persons have
been vaccinated more than 5 years ago they should
receive a booster. The risk population is identi-
cal to the risk-population described above for
influenza vaccination. Additionally patients with
functional or anatomic asplenia should be vacci-
nated [26].
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Screening
It is important to note that for most screening
interventions in medical practice, there is still in-
sufficient evidence whether these interventions
improve outcome. Therefore the physician often
needs to consider other factors than scientific evi-
dence in determining whether to offer a preven-
tive measure. Particularly for asymptomatic pa-
tients, thresholds for performing preventive serv-
ices differ depending on their potential for harm
in the absence of strong evidence of benefit. The
conditions required to recommend a screening test
are shown in table 4.
Screening recommended 
(Recommendation A and B)
Hypertension (USA and CAN: A). Screening
for hypertension is recommended for all persons
over age 20 at least biannually. There is good evi-
dence supporting this recommendation, which
shows that medical intervention in the asympto-
matic stage reduces both mortality and morbidity
from cardiovascular disease [31, 32].
Hypercholesterolaemia (USA and CAN: A). In
persons without other risk factors for coronary
heart disease screening for hypercholesterolaemia
should be performed in five year intervals starting
at age 35 for men and 45 for women. Several large
studies have shown that patients with high total
cholesterol or low HDL cholesterol who took cho-
lesterol-lowering drugs for 5–7 years decreased
their risk of heart disease by about 30% [33, 34].
The evidence for cholesterol screening in women
is based on weaker evidence [35]. The recom-
mended 5 year screening interval is based on ex-
pert opinion [36, 37].
Breast cancer (USA and CAN: A). Screening for
breast cancer with annual mammography in
women between age 50 and 70 is recommended by
both North American Task Forces [6–9]. Several
randomised studies including over 500’000 women
have shown a reduction from breast cancer related
mortality through annual mammography screen-
ing between 17–35% [38–41]. In most of these
studies screening mammography was combined
with clinical breast examination. An interesting
study recently published showed that women who
had annual mammography plus clinical breast ex-
amination between age 50 and 59 did not have a
lower mortality than the control group which was
screened with clinical breast examination alone
[42]. A recent meta-analysis showed that most of
the Scandinavian trials supporting screening
mammography had methodological flaws, and that
two adequately randomised trials found no effect
of screening on breast-cancer mortality [43]. In the
light of these new data the Swiss Cancer League is
currently discussing its implementation of mam-
mography screening. For women between age 40
and 49 the evidence supporting screening mam-
mography is weaker. Screening in this group is
given a “B” recommendation by the USPSTF [9]
and a “C” recommendation by the CTF [7]. Breast
self-examination appears to be less sensitive than
mammography or a clinical breast examination for
detecting breast cancer. But evidence is lacking to
advocate for or against teaching breast self exami-
nation as a screening tool [6–9].
Colorectal cancer (FOBT: USA and CAN: A;
Colonoscopy: USA and CAN: C). Colorectal can-
cer develops over years through a well known se-
quence with a defined precursor lesion, the ade-
noma. This asymptomatic sequence, the correla-
tion of survival with the stage of the disease and the
high incidence and prevalence make it an ideal can-
didate for screening. Thus, the USPSTF as well as
the Swiss Cancer League recommend screening
for colorectal cancer for all persons aged 50 or
older [7, 44]. Available screening tests are the
FOBT and colonoscopy. In Switzerland sigmoi-
doscopy is not used as frequently as in North
America for colorectal cancer screening. A large
randomised trial involving over 46000 volunteers
over age 50 found that the 13-year cumulative
mortality from colorectal cancer was 33% lower in
the group undergoing annual FOBT [45]. How-
ever, it is difficult to determine to what extent the
large number of colonoscopies performed in this
trial produced this reduction in mortality. Based on
this and several other trials [46, 47], annual FOBT
in persons age 50 and older receives a “B” recom-
mendation from the USPSTF and a “C” recom-
mendation from the CTF. So far evidence evalu-
ating colonoscopy as a screening intervention for
colorectal cancer is only indirect and both task
forces recommend neither for nor against it (“C”)
[48]. However, the recommendations regarding
colonoscopic screening are in flux and recent data
suggest that it might be at least as cost-effective as
the other approaches [49–51].
Cervical cancer (USA: A; CAN: B). Screening
for cervical cancer with Papanicolaou smear is rec-
ommended for all women who are sexually active
in three year intervals. Evidence from both cohort
and case-control studies have shown to reduce the
incidence of invasive disease through screening by
20 to 60%. This large body of indirect evidence
makes the performance of a randomised controlled
trial unlikely for ethical reasons [52, 53].
Obesity (USA: A; CAN: C). Periodic weight
and height measurements and calculation of the
body mass index (BMI) is recommended for all
adults by the USPSTF. There is insufficient evi-
dence to recommend a specific screening interval.
Obesity has been clearly linked to increased mor-
bidity and mortality [54, 55]. Most randomised
studies on weight reduction therapy show a short
term success, but a lack of effectiveness after long
term follow-up [56]. Thus screening for the con-
dition was only given a “C” recommendation by
the CTF [6].
Screening not recommended
(Recommendation D and E)
Lung cancer. There is fair (USA and CAN: D)
evidence to recommend against the use of chest 
x-ray for screening asymptomatic adults for lung
cancer. There is good evidence (USA and CAN: E)
to recommend against screening for the condition
with sputum cytology. Both screening interven-
tions were studied in the general population and in
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Table 4
Required prerequi-
sites for screening
[3].
The condition must have a significant effect on the quality and quantity of life
Acceptable methods of treatment must be available
The condition must have an asymptomatic period during which detection and treatment significantly 
reduce morbidity or mortality
Treatment in the asymptomatic phase must yield a therapeutic result superior to that obtained by delaying 
treatment until symptom appear
Tests that are acceptable to patients must be available, at a reasonable cost, to detect the condition
in the asymptomatic period
smokers. Although early-stage, resectable tumors
were found more frequently in the intervention
groups, mortality rates in the intervention and
control groups did not differ significantly for both
chest x-ray and sputum cytology [57, 58]. Large
RCTs assessing screening for lung cancer with low
dose spiral computed tomography are currently in
progress [59].
Pancreatic cancer (USA and CAN: D). Screen-
ing for pancreatic cancer using abdominal palpa-
tion, imaging studies (ultrasound, computerised
tomography or magnetic resonance imaging) or
tumour markers (CA 19-9) in asymptomatic per-
sons is not recommended. A study of mass screen-
ing of more than 10 000 asymptomatic persons
using either ultrasonography alone or CA 19-9
plus elastase-1 found the likelihood of pancreatic
cancer in the presence of a positive test to be only
0.5% [60]. Evidence that early detection of pan-
creatic cancer lowers morbidity and mortality is
not conclusive and most studies suffer from lead-
time, length or selection biases [6, 8]. 
Ovarian cancer (USA and CAN: D). Screening
asymptomatic women for ovarian cancer with
ultrasound, measurement of CA 125, or pelvic ex-
amination is not recommended. In a retrospective,
blinded study from Norway, sera from women who
later developed ovarian cancer was compared with
sera from matched controls. In this study the CA
125 had only a sensitivity of 30–35% [61]. Fur-
thermore, due to the low specificity of the CA 125
a large proportion of women undergoing screen-
ing would be tested false positive [62]. These
women would require further invasive procedures
(laparoscopy or laparotomy) with substantial costs
and risks [6–9].
Coronary heart disease (USA and CAN: D). Cer-
tain ECG findings (ST depression, T-wave inver-
sion, Q waves and left axis deviation) are associated
with increased likelihood of coronary atheroscle-
rosis being present. They are not specific and
occur only in 1–4% of asymptomatic men with
coronary artery disease (CAD) [63]. Prospective
studies have shown that only 3–15% of patients
with these abnormalities in the ECG develop
symptomatic CAD during follow-up periods be-
tween 5 and 30 years [64, 65]. The availability of a
baseline screening ECG in patients presenting
with chest pain and no history of CAD did not alter
the clinical decision making [66]. The exercise
ECG has better operating characteristics but has
an unacceptable high cost to be used as a test for
mass screening. 
Controversial topics
As is evident from the above, only a small num-
ber of screening interventions can be clearly advo-
cated or discarded. For most interventions a “C”-
recommendation is given. Some of these contro-
versial topics are discussed in this chapter.
Diabetes mellitus 2 (USA: C; CAN: D). So far
evidence of a benefit of early detection of diabetes
mellitus is lacking. Evidence from a randomised
controlled trial is unlikely to emerge due to ethi-
cal reasons though. Furthermore the fasting
plasma glucose as a screening test is not sufficiently
sensitive (21–75%) [67, 68]. Sensitivities for 
HbA1c are in a similar range (15–93%) [69]. For
these reasons the CTF does not recommend
screening. The USPSTF states that there is insuf-
ficient evidence to recommend for or against
screening. The American Diabetes Association
(ADA) has a different approach and recommends
screening the general population in a clinical
setting every 3 years starting at age 45 [70]. This
recommendation is based on expert consensus.
The same group recommends against community
screening outside a clinical setting. There is evi-
dence that screening and treating certain high risk
groups for diabetes mellitus is beneficial. High-
risk groups include persons with a BMI >27 kg/m2,
hyperlipidaemia, hypertension, polycystic ovary
syndrome, positive family history and of certain
ethnicity (black, Asian-pacific) [70].
Thyroid disorder (USA: D; CAN: C). In women
older than 50 years thyroid dysfunction, especially
hypothyroidism, has a high enough prevalence to
warrant screening [71, 72]. The TSH assay has a
good sensitivity and specificity. Whether therapy
in the asymptomatic phase has an effect on the out-
come used to be in dispute. There is now, however,
emerging evidence that a considerable number of
individuals with subclinical hypothyroidism in fact
have symptoms. These trials also have demon-
strated that treatment with thyroxine improves
these symptoms and prevents overt hypothy-
roidism [73–75]. In the light of these new data,
case-finding in women over 50 should be strongly
considered.
Prostate cancer (USA and CAN: D). Currently
the best available screening strategy for prostate
cancer involves measurement of serum prostate
specific antigen (PSA), followed by transrectal
ultrasound and biopsy. This combined approach
still lacks adequate specificity and sensitivity [76].
Given that prostate cancer is very common at au-
topsy and that a tumour smaller than 1.0 ml is not
likely to result in an elevated PSA, tumours are
possibly found simply by chance in men with an el-
evated PSA (the concentration of the PSA being
related to the amount of benign prostatic hyper-
plasia) [77]. Furthermore, there is lack of evidence
whether early treatment in the asymptomatic
phase improves life expectancy and quality of life
[78]. Screening does not necessarily lead to treat-
ment, since watchful waiting is a possible thera-
peutic option in small, well differentiated prostate
cancers [77]. Since the disease can have a long
asymptomatic period and also a heterogeneous
course it is a perfect example of lead time and
length bias. 
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The “Check-up” as a reason for consultation
is often used by patients to raise the issue of a spe-
cific problem that troubles them, i.e., patients may
have a hidden agenda. There are some small stud-
ies, which have investigated this issue [79–81].
From those patients who present for a “Check-up”
only 25% know about the concept of detecting dis-
ease in an asymptomatic phase. More than half of
these patients have specific questions or wishes
they want to have addressed and 45% do have
psychosocial problems upon further questioning.
Doctors need to be aware of this and address the
patient’s possible hidden agenda, such as a request
for an HIV test or specific fears.
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Conclusion
Primary prevention rather than secondary
prevention should be the focus of each patient en-
counter, but especially during a check-up or peri-
odic health exam. Interventions that address pa-
tients’ personal health practices are vitally impor-
tant and influence the patients’ future health at
least as much as the more expensive secondary pre-
ventive measures. Each preventive intervention,
including those which are based on strong evi-
dence from RCTs, should be discussed with the pa-
tient regarding the absolute risk reductions and
potential side effects from labelling, investigations
or therapy. Involvement of the patient in the deci-
sion-making ensures long lasting success. Sec-
ondary preventive measures, including screening,
are to be tailored individually to a patients’ risk
profile and clinicians should be selective in order-
ing tests.
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